港股公告掘金 | 云顶新耀：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态

智通财经2025-12-30

重大事项：云顶新耀(01952)：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595713426?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-30 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595713426","market":"fut","top_or_hot":-1,"title":"港股公告掘金 | 云顶新耀：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态","media":"智通财经","content":"<div>\n<p>重大事项：云顶新耀(01952)：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387378.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股公告掘金 | 云顶新耀：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股公告掘金 | 云顶新耀：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-30 22:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1387378.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>重大事项：云顶新耀(01952)：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1387378.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01952","symbol_name":"云顶新耀","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1387378.html","article_id":"2595713426","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595713426","pubTimestamp":1767106552,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"重大事项：云顶新耀(01952)：原研产品耐赋康的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗一体","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01952":"云顶新耀","00013":"和黄医药","BK1583":"高瓴概念","BK1593":"医美概念股","BK1161":"生物科技","BK1191":"制药","BK1515":"抗疫概念","BK1588":"回港中概股","BK1587":"次新股","BK1574":"生物医药B类股","02196":"复星医药","00690":"联康生物科技集团"},"translate_title":"Hong Kong Stock Announcement Nuggets | Genting Xinyao: Original research product Naifukang ® The related technology is protected by patent ZL200980127272.5 in China, which is currently valid","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01952":1.5,"02196":0.9,"00690":0.9,"00013":0.9},"content_text":"重大事项：云顶新耀(01952)：原研产品耐赋康®的相关技术在中国受到专利ZL200980127272.5的保护，该专利目前处于有效状态联康生物科技集团(00690)与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作和黄医药(00013)宣布赛沃替尼 (savolitinib) 用于治疗伴有MET扩增的胃癌患者的中国新药上市申请获受理并获纳入优先审评复星医药(02196)控股子公司就诊疗一体化核药项目SRT-007 于中国境内启动Ⅰ期临床试验邮储银行(01658)吸收合并邮惠万家银行获国家金融监督管理总局批准微创心通-B(02160)：AltaValveTM早期可行性研究一年随访结果正式公布经营业绩：新火科技控股(01611)公布年度业绩 公司拥有人应占亏损921.2万港元 同比盈转亏星谦发展(00640)公布年度业绩 净利约1.22亿港元 同比增长21.7%紫金矿业(02899)预计2025年度归母净利润约510亿—520亿元，同比增加约59%—62%紫金黄金国际(02259)发盈喜 预期2025年归母净利约15-16亿美元 同比增加约212%-233%","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595713426","isCrawlerRequest":true}